Sarah Bertoli
Overview
Explore the profile of Sarah Bertoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petit C, Higue J, Acheaibi Z, Gilhodes J, Hospital M, Devillier R, et al.
Am J Hematol
. 2025 Mar;
PMID: 40088036
No abstract available.
2.
Brousse X, Rasandisona N, Berard E, Leroy H, Delavigne K, Mottal N, et al.
Open Forum Infect Dis
. 2025 Mar;
12(3):ofaf105.
PMID: 40070813
Objectives: Antibiotic prophylaxis for patients with cancer remains a controversial issue and is not broadly recommended for hematological malignancies. The venetoclax (VEN) and azacitidine (AZA) combination allows for high rates...
3.
Bertoli S, Berard E, Peterlin P, Guieze R, Desbrosses Y, Hicheri Y, et al.
Haematologica
. 2025 Feb;
PMID: 39911128
Not available.
4.
Recher C, Dumas P, Berard E, Tavitian S, Leguay T, Galtier J, et al.
Am J Hematol
. 2024 Nov;
100(1):23-32.
PMID: 39555737
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of...
5.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahme R, Bertoli S, et al.
Blood Adv
. 2024 Oct;
9(4):752-758.
PMID: 39454204
CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on measurable residual disease (MRD) and long-term...
6.
Joudinaud R, Boudry A, Fenwarth L, Geffroy S, Salson M, Dombret H, et al.
Blood Adv
. 2024 Oct;
9(2):365-374.
PMID: 39418643
Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60%...
7.
Jeanselme P, Tavitian S, Lapierre L, Vergez F, Rigolot L, Huynh A, et al.
Leuk Lymphoma
. 2024 Aug;
65(13):2025-2030.
PMID: 39141583
Adult T-cell acute lymphoblastic leukemia has a poor outcome after relapse. Because the subtype of early T-cell precursor displays characteristics close of those of acute myeloid leukemia, such as epigenetic...
8.
Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas P, Iat A, et al.
Leukemia
. 2024 Jul;
38(9):1949-1957.
PMID: 39020060
Patients with Core-Binding Factor (CBF) and NPM1-mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive...
9.
Garciaz S, Dumas P, Bertoli S, Sallman D, Decroocq J, Belhabri A, et al.
Am J Hematol
. 2024 Jun;
99(10):1870-1876.
PMID: 38899566
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration...
10.
Le Grand S, Canali A, Bertoli S, Recher C, De Mas V, Rieu J
EJHaem
. 2024 Jun;
5(3):635-637.
PMID: 38895076
No abstract available.